Medizinische Klinik

, Volume 105, Issue 2, pp 111–117 | Cite as

Journal Club

JOURNAL CLUB
  • 31 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238–48.CrossRefPubMedGoogle Scholar
  2. 2.
    Fellström BC, Jardine AG, Schmieder RE, et al., AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395–407.CrossRefPubMedGoogle Scholar
  3. 3.
    Baigent C, Keech A, Kearney PM, et al., Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78.CrossRefPubMedGoogle Scholar
  4. 4.
    Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001;38:Suppl 1:S26–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Herzog CA, Littrell K, Arko C, et al. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 2007;116:1465–72.CrossRefPubMedGoogle Scholar
  6. 6.
    Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003;84:S207–10.CrossRefPubMedGoogle Scholar

Literatur

  1. 1.
    Wheatley K, Ives N, Gray R, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009;361:1953–62.CrossRefPubMedGoogle Scholar
  2. 2.
    Textor SC. Renovascular hypertension in 2007: where are we now? Curr Cardiol Rep 2007;9:453–61.CrossRefPubMedGoogle Scholar
  3. 3.
    Wierema TK, Yaqoob MM. Renal artery stenosis in chronic renal failure: caution is advised for percutaneous revascularization. Eur J Intern Med 2008;19:276–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Ives NJ, Wheatley K, Stowe RL, et al. Continuing uncertainty about the value of percutaneous revascularization in atherosclerotic renovascular disease: a meta-analysis of randomized trials. Nephrol Dial Transplant 2003;18:298–304.CrossRefPubMedGoogle Scholar
  5. 5.
    Plouin PF, Rossignol P, Bobrie G. Atherosclerotic renal artery stenosis: to treat conservatively, to dilate, to stent, or to operate? J Am Soc Nephrol 2001;12:2190–6.PubMedGoogle Scholar
  6. 6.
    van Jaarsveld BC, Krijnen P, Pieterman H, et al., Dutch Renal Artery Stenosis Intervention Cooperative Study Group. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. N Engl J Med 2000;342:1007–14.CrossRefPubMedGoogle Scholar
  7. 7.
    Plouin PF, Chatellier G, Darne B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group. Hypertension 1998;31:823–9.PubMedGoogle Scholar
  8. 8.
    van Jaarsveld B, Krijnen P, Bartelink A, et al. The Dutch Renal Artery Stenosis Intervention Cooperative (DRASTIC) Study: rationale, design and inclusion data. J Hypertens Suppl 1998;16:S21–7.PubMedGoogle Scholar
  9. 9.
    Webster J, Marshall F, Abdalla M, et al. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens 1998;12:329–35.CrossRefPubMedGoogle Scholar

Literatur

  1. 1.
    Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085–98.CrossRefPubMedGoogle Scholar
  2. 2.
    Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071–84.CrossRefPubMedGoogle Scholar
  3. 3.
    Pfeffer MA, Burdmann EA, Chen CY, et al., TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019–32.CrossRefPubMedGoogle Scholar
  4. 4.
    Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791–8.CrossRefPubMedGoogle Scholar

Literatur

  1. 1.
    Bijkerk CJ, de Wit NJ, Muris JW, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ 2009;339:b3145.CrossRefGoogle Scholar

Literatur

  1. 1.
    Holmes DR, Reddy VY, Turi ZG, et al., PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534–42.CrossRefPubMedGoogle Scholar

Copyright information

© Urban & Vogel, Muenchen 2010

Personalised recommendations